Vyas D, Laput G, Vyas A. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. OncoTargets Ther. 2014;7:1015–23.

Article  Google Scholar 

Volk-Draper L, Hall K, Griggs C, Rajput S, Kohio P, DeNardo D, et al. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res. 2014;74:5421–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009;28:4353–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mirzaei SA, Dinmohammadi F, Alizadeh A, Elahian F. Inflammatory pathway interactions and cancer multidrug resistance regulation. Life Sci. 2019;235:116825.

Article  CAS  PubMed  Google Scholar 

Ran S. The role of TLR4 in chemotherapy-driven metastasis. Cancer Res. 2015;75:2405–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.

Article  CAS  PubMed  Google Scholar 

Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner. Cancer Cell. 2010;17:135–47.

Article  CAS  PubMed  Google Scholar 

Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med. 2013;210:2851–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sangaletti S, Di Carlo E, Gariboldi S, Miotti S, Cappetti B, Parenza M, et al. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res. 2008;68:9050–9.

Article  CAS  PubMed  Google Scholar 

Croix BS, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science. 2000;289:1197–202.

Article  Google Scholar 

Langenkamp E, Molema G. Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res. 2009;335:205–22.

Article  CAS  PubMed  Google Scholar 

Ohga N, Ishikawa S, Maishi N, Akiyama K, Hida Y, Kawamoto T, et al. Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors. Am J Pathol. 2012;180:1294–307.

Article  CAS  PubMed  Google Scholar 

Maishi N, Ohba Y, Akiyama K, Ohga N, Hamada JI, Nagao-Kitamoto H, et al. Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan. Sci Rep. 2016;6:28039.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akiyama K, Ohga N, Hida Y, Kawamoto T, Sadamoto Y, Ishikawa S, et al. Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. Am J Pathol. 2012;180:1283–93.

Article  CAS  PubMed  Google Scholar 

Akiyama K, Maishi N, Ohga N, Hida Y, Ohba Y, Alam MT, et al. Inhibition of multidrug transporter in tumor endothelial cells enhances antiangiogenic effects of low-dose metronomic paclitaxel. Am J Pathol. 2015;185:572–80.

Article  CAS  PubMed  Google Scholar 

Hida K, Maishi N, Akiyama K, Ohmura-Kakutani H, Torii C, Ohga N, et al. Tumor endothelial cells with high aldehyde dehydrogenase activity show drug resistance. Cancer Sci. 2017;108:2195–203.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kikuchi H, Maishi N, Annan DA, Alam MT, Dawood RIH, Sato M, et al. Chemotherapy-induced IL-8 upregulates MDR1/ABCB1 in tumor blood vessels and results in unfavorable outcome. Cancer Res. 2020;80:2996–3008.

Article  CAS  PubMed  Google Scholar 

Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63:4342–6.

CAS  PubMed  Google Scholar 

Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, et al. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother. 2013;62:383–91.

Article  CAS  PubMed  Google Scholar 

Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol. 2002;13:12–15.

Article  CAS  PubMed  Google Scholar 

Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O’Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878–86.

CAS  PubMed  Google Scholar 

Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Investig. 2000;105:1045–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62:6938–43.

CAS  PubMed  Google Scholar 

Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–36.

Article  CAS  PubMed  Google Scholar 

Lutsiak MC, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862–8.

Article  CAS  PubMed  Google Scholar 

Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641–8.

Article  CAS  PubMed  Google Scholar 

Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 2009;69:6987–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hasnis E, Alishekevitz D, Gingis-Veltski S, Bril R, Fremder E, Voloshin T, et al. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy. Neoplasia. 2014;16:501–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan TS, Hsu CC, Pai VC, Liao WY, Huang SS, Tan KT, et al. Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. J Exp Med. 2016;213:2967–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang CL, Hsu YT, Wu CC, Lai YZ, Wang C, Yang YC, et al. Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res. 2013;73:119–27.

Article  CAS  PubMed  Google Scholar 

Ju X, Zhang H, Zhou Z, Chen M, Wang Q. Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling. Exp Cell Res. 2020;396:112315.

Article  CAS  PubMed  Google Scholar 

Zhang W, Liu Y, Yan Z, Yang H, Sun W, Yao Y, et al. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. J ImmunoTher Cancer. 2020;8:e000285.

Article  PubMed  PubMed Central  Google Scholar 

Häuselmann I, Roblek M, Protsyuk D, Huck V, Knopfova L, Grässle S, et al. Monocyte induction of E-selectin–mediated endothelial activation releases ve-cadherin junctions to promote tumor cell extravasation in the metastasis cascade. Cancer Res. 2016;76:5302–12.

Article  PubMed  PubMed Central  Google Scholar 

Kerbel RS, Shaked Y. The potential clinical promise of ‘multimodality’ metronomic chemotherapy revealed by preclinical studies of metastatic disease. Cancer Lett. 2017;400:293–304.

Article  CAS  PubMed  Google Scholar 

Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, et al. Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future? OncoTargets Ther. 2019;12:2989–97.

Article  CAS  Google Scholar 

Von Der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versu